人 EFNA4 抗体对
01AB01472
Ephrin A4 (EFNA4) is a glycosylphosphatidylinositol (GPI)-anchored ligand for Eph receptors, belonging to the ephrin family. It is a 17.5 kDa protein that migrates to 18-25 kDa due to glycosylation. EFNA4 binds to multiple EphA receptors, including EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, and EphB1. The protein plays crucial roles in cell migration, repulsion, and adhesion during development, particularly in the nervous system and erythropoiesis. EFNA4 is expressed in various tissues and has been implicated in cancer progression. In hepatocellular carcinoma, EFNA4 suppression inhibits cell proliferation, invasion, and angiogenesis by downregulating PYGO2. Additionally, EFNA4-EphA10 signaling promotes cell migration and spheroid formation in oral squamous cell carcinoma by upregulating NANOG expression. EFNA4 has also been associated with craniofrontonasal syndrome and craniosynostosis.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- EFNA4
- 基因别名
- EPLG4; LERK4
- 蛋白别名
- ephrin A4; EFNA4
- UniProt
- P52798
- 物种
- Human
产品详情
- 靶点名称
- EFNA4
- 蛋白名称
- ephrin A4
- 蛋白别名
- Ephrin-A4; EPH-related receptor tyrosine kinase ligand 4; LERK-4
- 靶点基因名
- EFNA4
- 基因别名
- EPLG4; LERK4
- UniProt
- P52798
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Ephrin A4 (EFNA4) is a glycosylphosphatidylinositol (GPI)-anchored ligand for Eph receptors, belonging to the ephrin family. It is a 17.5 kDa protein that migrates to 18-25 kDa due to glycosylation. EFNA4 binds to multiple EphA receptors, including EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, and EphB1. The protein plays crucial roles in cell migration, repulsion, and adhesion during development, particularly in the nervous system and erythropoiesis. EFNA4 is expressed in various tissues and has been implicated in cancer progression. In hepatocellular carcinoma, EFNA4 suppression inhibits cell proliferation, invasion, and angiogenesis by downregulating PYGO2. Additionally, EFNA4-EphA10 signaling promotes cell migration and spheroid formation in oral squamous cell carcinoma by upregulating NANOG expression. EFNA4 has also been associated with craniofrontonasal syndrome and craniosynostosis.